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Adiponutrin (PNPLA3) is a predominantly liver-expressed transmembrane protein with phospholipase
activity that is regulated by fasting and feeding. Recent genome-wide association studies identified
PNPLA3 to be associated with hepatic fat content and liver function, thus pointing to a possible involvement
in the hepatic lipoprotein metabolism. The aim of this study was to examine the association between two
common variants in the adiponutrin gene and parameters of lipoprotein metabolism in 23 274 participants
from eight independent West-Eurasian study populations including six population-based studies [Bruneck
(n 5 800), KORA S3/F3 (n 5 1644), KORA S4/F4 (n 5 1814), CoLaus (n 5 5435), SHIP (n 5 4012), Rotterdam
(n 5 5967)], the SAPHIR Study as a healthy working population (n 5 1738) and the Utah Obesity Case-
Control Study including a group of 1037 severely obese individuals (average BMI 46 kg/m2) and 827 controls
from the same geographical region of Utah. We observed a strong additive association of a common non-
synonymous variant within adiponutrin (rs738409) with age-, gender-, and alanine-aminotransferase-adjusted
lipoprotein concentrations: each copy of the minor allele decreased levels of total cholesterol on average by
2.43 mg/dl (P 5 8.87 3 1027), non-HDL cholesterol levels by 2.35 mg/dl (P 5 2.27 3 1026) and LDL cholesterol
levels by 1.48 mg/dl (P 5 7.99 3 1024). These associations remained significant after correction for multiple
testing. We did not observe clear evidence for associations with HDL cholesterol or triglyceride concen-
trations. In conclusion, our study suggests that adiponutrin is involved in the metabolism of apoB-containing
lipoproteins.
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INTRODUCTION
Adiponutrin (PNPLA3) is a predominantly liver-expressed
transmembrane protein with phospholipase activity (1–3). It
is upregulated during adipocyte differentiation and in response
to feeding and downregulated in fasting state, indicating a
potential role in lipid storage in adipose tissue and liver (1–
5). An increased energy intake, either acute or long-lasting,
leads to an upregulation of adiponutrin (6). In vitro adiponu-
trin gene expression shows features of lipogenic gene
expression comparable to fatty acid synthase or adipocyte
determination and differentiation of factor-1/sterol regulatory
element binding protein-1c (ADD1/SREBP1c) (1). The
common non-synonymous variant rs738409 results in an
amino acid exchange from isoleucine to methionine in the cat-
alytic patatin domain (see Supplementary Material, Fig. S1
and reference 7). Additionally, rs738409 was reported to acti-
vate a putative exonic splicing silencer element and might
therefore also affect gene regulation (8). A further SNP,
rs2072907, in linkage disequilibrium with rs738409, was
reported to be associated with obesity (9).
Recent genome-wide association studies identified the adi-
ponutrin gene to be associated with liver-related phenotypes
(7,10). Romeo et al. (7) found carriers of the minor allele of
rs738409 to have a significantly increased hepatic fat
content in a population of Hispanic, African-American and
European-American individuals and significantly higher liver
enzymes in Hispanics which points to an important role of adi-
ponutrin in the hepatic lipoprotein metabolism. These obser-
vations and the experimental findings described above make
adiponutrin an interesting candidate gene involved in lipid
metabolism.
In the present candidate gene study, we aimed to investigate
the association of rs738409 and rs2072907 of the adiponutrin
gene with lipid parameters in eight independent populations
including 23 274 individuals, representing six population-
based studies, a healthy working population and a case–
control study of a severely obese population.
RESULTS
Patient and genotype characteristics
Baseline clinical characteristics and laboratory data of the
eight study populations are reported in Table 1 and are strati-
fied by case–control status for the Utah Obesity Case-Control
Study. The minor allele frequencies ranged from 18.5 to
30.0% for rs738409 and from 16.2 to 24.9% for rs2072907
across the populations (Table 1). Due to these differences in
minor allele and genotype frequencies between populations
in our and earlier studies (7,10) and due to differences in the
lipid levels between populations, the analysis was performed
stratified for the eight populations.
Association of rs738409 and rs2072907 within adiponutrin
and lipid levels
Supplementary Material, Tables S1 and S2 show the age-,
gender- and alanine-aminotransferase-adjusted lipid levels
using an unconstrained model (not assuming any genetic
mode of inheritance) for the three genotypes of the exonic
adiponutrin SNP rs738409 and the intronic SNP rs2072907,
respectively. Calculation of l as the quotient of the
b-coefficients of heterozygote and homozygote carriers of
the minor allele of the unconstrained model revealed an addi-
tive mode of inheritance in most of the populations (as an
example, see results for rs738409 in Supplementary Material,
Table S3). Therefore, the main analyses and meta-regression
were based on the additive inheritance assumption. Table 2
shows the b-estimates and P-values from linear regression
models applying an additive model, once adjusted for age
and gender and once additionally adjusted for the liver
enzyme alanine-aminotransferase. We observed that the
minor allele was associated with lower concentrations of
total cholesterol (TC), non-HDL cholesterol (non-HDLC)
and LDL cholesterol (LDLC). Since the associations became
even stronger when additionally adjusted for
alanine-aminotransferase, we assumed that the association of
these adiponutrin SNPs with lipid levels is not a secondary
effect of liver impairment. Using a fixed effects model, each
copy of the minor allele decreased total cholesterol levels by
on average of 2.43 mg/dl (P ¼ 8.87  1027), non-HDL
cholesterol levels by 2.35 mg/dl (P ¼ 2.27  1026) and LDL
cholesterol levels by 1.48 mg/dl (P ¼ 7.99  1024). In
addition, we observed a trend for lower triglyceride (TG)
levels per copy of the minor allele (estimate on the log scale
20.011, P ¼ 0.10) but no association with HDLC concen-
trations. After correction for multiple testing, the effects on
total cholesterol, non-HDLC and LDLC remained statistically
significant. When we analyzed the data for triglycerides in the
Utah Obesity Case-Control Study, we observed lower trigly-
ceride levels per copy of the minor allele which was more pro-
nounced in the cases than in the controls (estimate 20.073,
P ¼ 0.008 for cases, and 20.019, P ¼ 0.54 for controls).
However, this interaction was not significant, and furthermore,
after correction for multiple testing, the effect for triglycerides
was no longer significant.
Similar associations were observed for rs2072907 (Table 2).
Moreover, an additional adjustment for BMI revealed similar
estimates for both SNPs. When we repeated the analysis
using a random effects model, we observed similar beta esti-
mates as for the fixed effects model.
Bioinformatic analysis
To investigate whether or not adiponutrin interacted directly
with cholesterol, we used the BioSapiens DASTY tool,
which integrates several tools for protein domain analysis.
No direct cholesterol-binding domains could be observed
(Supplementary Material, Fig. S1).
Since data mining using STRING 8.0 suggested among
others an interaction of adiponutrin with lipoprotein lipase
(LPL) and hepatic lipase (LIPC) (see Supplementary Material,
Fig. S2), we investigated a potential co-regulation of the adi-
ponutrin promoter with cholesterol metabolism given that
co-regulation and shared transcription factor binding sites
often point to a functional interaction (11,12). For this
purpose, the adiponutrin promoter was predicted using the
Genomatix Promoter Inspector tool and searched for the pres-
ence of putative transcription factor binding sites involved in
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Table 1. Clinical and laboratory data of participants of the Bruneck Study, KORA S3/F3 Study, KORA S4/F4 Study, CoLaus Study, SHIP, Rotterdam Study, SAPHIR Study and Utah Obesity Case-Control
Study with further stratification of the latter in patients with severe obesity and controls
Bruneck Study
(n ¼ 800)
KORA S3/F3 Study
(n ¼ 1644)
KORA S4/F4 Study
(n ¼ 1814)
CoLaus Study
(n ¼ 5435)
SHIP (n ¼ 4012) Rotterdam Study
(n ¼ 5967)
SAPHIR Study
(n ¼ 1738)
Utah Obesity Case-Control Study
Severe obesity
(n ¼ 1037)
Controls (n ¼ 827)
Age, years 62.7+ 11.1 62.5+ 10.1 60.9+ 8.9 53.5+ 10.8 49.7+ 16.3 69.4+ 9.1 51.8+ 6.1 44.3+ 11.4 52.7+ 8.5
Gender: male/female,
n (%)
398/402
(49.8/50.2)
813/831
(49.4/50.6)
884/930
(48.7/51.3)
2560/2875
(47.1/52.9)
1972/2040
(49.2/50.8)
2359/3465
(40.5/59.5)
1093/645
(62.9/37.1)
194/843
(18.7/81.3)
399/428
(48.2/51.8)
rs738409: CC/CG/GG
n (%) 381/343/65
(48.3/43.5/8.2)
941/613/90
(57.2/37.3/5.5)
1193/571/50
(65.7/31.5/2.8)
3074/2037/324
(56.6/37.5/5.9)
2391/1432/189
(59.6/35.7/4.7)
3647/2078/242
(61.1/34.8/4.1)
885/720/105
(51.8/42.1/6.1)
612/366/45
(59.8/35.8/4.4)
468/272/44
(59.7/34.7/5.6)
MAF 30.0 24.1 18.5 24.7 22.8 21.5 27.2 22.3 23.0
Call rate (%) 98.6 100a 100a 100a 100a 99.9 98.0 98.6 94.8
rs2072907: CC/CG/GG
n (%) 464/272/43
(59.6/34.9/5.5)
1104/490/50
(67.2/29.8/3.0)
1015/694/105
(55.9/38.3/5.8)
3641/1624/170
(67.0/29.9/3.1)
2674/1212/126
(66.7/30.2/3.1)
3979/1773/222
(66.6/29.7/3.7)
1086/553/73
(63.4/32.3/4.3)
715/287/22
(69.8/28.0/2.2)
540/219/26
(68.8/27.9/3.3)
MAF 23.0 17.9 24.9 18.1 18.3 18.5 20.4 16.2 17.3
Call rate (%) 97.4 100a 100a 100a 100a 100a 98.1 98.7 94.9
Body mass index, kg/m2 25.6+ 3.8 28.1+ 4.5 28.2+ 4.8 25.9+ 4.6 27.3+ 4.7 26.3+ 3.7 26.8+ 4.1 46.0+ 7.6 27.6+ 4.9
Total cholesterol, mg/dl 230.0+ 42.6 221.3+ 40.3 221.8+ 39.3 224.0+ 41.3 222.9+ 47.8 255.1+ 47.2 228.6+ 40.1 186.8+ 36.2 187.1+ 33.9
Non-HDL cholesterol, mg/dl 171.3+ 42.9 163.2+ 40.0 165.3+ 38.5 153.9+ 41.0 166.8+ 49.2 203.2+ 47.4 169.0+ 41.8 140.8+ 35.1 137.0+ 33.6
HDL cholesterol, mg/dl 58.7+ 16.2 58.0+ 16.9 56.5+ 14.5 63.6+ 17.0 56.09+ 16.6 51.8+ 14.3 59.6+ 15.7 46.0+ 11.0 50.1+ 15.0
LDL cholesterol, mg/dl 145.5+ 37.9 130.1+ 32.7 139.9+ 35.0 128.5+ 35.4 138.1+ 44.8 145.1+ 34.2 145.5+ 36.6 108.3+ 27.6 105.0+ 27.5
Alanine-aminotransferase,
(U/L) (25th; 50th; 75th
percentile)
23.1+ 13.1
(15;20;27)
20.4+ 11.4
(14;18;24)
26.4+ 16.2
(16;22;30)
27.7+ 19.5
(17;23;32)
30.0+ 18.0
(17;23;33)
18.0+ 11.4
(12;16;20)
17.4+ 10.6
(11;15;20)
27.9+ 17.4
(17,24;33)
25.8+ 13.6
(17;22;30)
Triglycerides, mg/dl (25th;
50th; 75th percentile)
131.7+ 71.9
(81;111;158)
142.3+ 123.2b
(85;115;163)
132.7+ 94.6b
(77,110;157)
123.9+ 104.8
(71;98;142)
–b 137.9+ 67.6b
(94; 122; 163)
125.6+ 87.7
(72;101;149)
186.1+ 105.6
(118;165;220)
156.0+ 105.0
(94;133;184)
Diabetes mellitus, n (%) 76 (9.5) 181 (11.0) 167 (9.2) 246 (4.5) 142 (3.5) 631 (10.6) 55 (3.2) 224 (21.6) 54 (6.5)
Use of lipid lowering drugs,
n (%)
25 (3.1) 238 (14.5) 299 (16.5) 636 (11.7) 317 (7.9) 150 (2.5) 79 (4.6) 122 (11.9) 65 (7.9)
Values are provided as mean and standard deviation if not indicated otherwise.
P , 0.05; P , 0.005; P , 0.001—comparison between severe obese subjects and controls in the Utah obesity case–control study.
aGenotypes were imputed with very high imputation quality [RSQR for MACH and proper_info for IMPUTE .0.90 (Kora S3/F3 and S4/F4), RSQR for MACH for the Rotterdam Study (.0.99), proper_info for IMPUTE for the CoLaus
Study .0.97 and for SHIP .0.96].
bTriglycerides are provided only for fasting participants which were 675 in KORA S3/F3, 1789 in KORA S4/F4, 5389 in CoLaus and 2038 in Rotterdam. Participants of SHIP were non-fasting at the time of blood collection.
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Table 2. Association between rs738409 (C.G) and rs2072907 (C.G) of the adiponutrin gene and lipid levels gene in the Bruneck Study, KORA S3/F3 and S4/
F4 Study, CoLaus Study, SHIP, Rotterdam Study, SAPHIR Study and Utah Obesity Case-Control Study (additive model)
Parameters/study rs738409 (C.G) rs2072907 (C.G)
Adjusted for age and gender Adjusted for age, gender and
ALT
Adjusted for age and gender Adjusted for age, gender and
ALT
b (SE) P-value b (SE) P-value b (SE) P-value b (SE) P-value
Total cholesterol, mg/dl
Bruneck Study 1.49 (2.40) 0.53 1.18 (2.40) 0.62 21.48 (2.54) 0.56 21.55 (2.54) 0.54
KORA S3/F3 Study 21.65 (1.72) 0.34 22.45 (1.73) 0.16 21.26 (1.91) 0.51 22.12 (1.92) 0.27
KORA S4/F4 Study 22.53 (1.58) 0.11 23.00 (1.59) 0.06 23.84 (1.80) 0.03 24.34 (1.80) 0.02
CoLaus Study 22.07 (0.96) 0.03 22.56 (0.96) 0.008 21.24 (1.07) 0.25 21.76 (1.07) 0.10
SHIP 22.04 (1.30) 0.12 23.18 (1.28) 0.01 21.61 (1.38) 0.24 22.44 (1.37) 0.07
Rotterdam Study 0.35 (1.05) 0.74 0.59 (1.24) 0.63 21.11 (1.09) 0.31 21.13 (1.27) 0.38
SAPHIR Study 22.89 (1.62) 0.08 23.46 (1.62) 0.03 23.33 (1.72) 0.05 23.71 (1.72) 0.03
Utah Cases 24.79 (2.05) 0.02 25.07 (2.07) 0.01 24.57 (2.31) 0.05 24.65 (2.32) 0.05
Utah Controls 25.67 (2.08) 0.007 25.62 (2.07) 0.007 23.04 (2.30) 0.19 22.97 (2.29) 0.20
Pooled analysisa 21.84 1.243 1024 22.43 8.873 1027, b 21.94 1.873 1024 22.41 7.013 1026, b
Non-HDL cholesterol, mg/dl
Bruneck Study 2.26 (2.44) 0.35 1.69 (2.42) 0.49 20.55 (2.59) 0.83 20.70 (2.57) 0.79
KORA S3/F3 Study 20.15 (1.73) 0.93 21.31 (1.74) 0.45 0.16 (1.92) 0.93 21.17 (1.93) 0.54
KORA S4/F4 Study 22.44 (1.58) 0.12 23.06 (1.58) 0.05 22.94 (1.79) 0.10 23.58 (1.79) 0.05
CoLaus Study 21.90 (0.96) 0.05 22.54 (0.95) 0.007 21.05 (1.06) 0.32 21.73 (1.05) 0.01
SHIP 22.28 (1.33) 0.09 23.52 (1.31) 0.007 22.00 (1.41) 0.16 22.89 (1.40) 0.04
Rotterdam Study 0.10 (1.08) 0.93 0.67 (1.26) 0.60 20.69 (1.12) 0.53 20.87 (1.30) 0.50
SAPHIR Study 22.80 (1.70) 0.10 23.80 (1.69) 0.03 22.64 (1.81) 0.14 23.32 (1.79) 0.06
Utah Cases 24.92 (2.00) 0.01 25.25 (2.01) 0.009 24.56 (2.25) 0.04 24.65 (2.26) 0.04
Utah Controls 24.51 (2.06) 0.03 24.51 (2.04) 0.03 21.76 (2.27) 0.44 21.73 (2.25) 0.44
Pooled analysisa 21.69 4.953 1024 22.35 2.273 1026, b 21.52 0.004 22.14 6.963 1025, b
LDL cholesterol, mg/dl
Bruneck Study 1.91 (2.14) 0.37 1.68 (2.14) 0.43 20.68 (2.26) 0.77 20.73 (2.26) 0.75
KORA S3/F3 Study 20.33 (1.41) 0.81 20.77 (1.42) 0.59 20.12 (1.57) 0.94 20.61 (1.58) 0.70
KORA S4/F4 Study 21.32 (1.43) 0.36 21.75 (1.44) 0.22 22.03 (1.63) 0.21 22.51 (1.63) 0.12
CoLaus Study 21.40 (0.82) 0.09 21.68 (0.83) 0.04 20.60 (0.91) 0.51 20.92 (0.92) 0.32
SHIP 21.39 (1.21) 0.25 22.15 (1.21) 0.07 21.01 (1.29) 0.43 21.56 (1.29) 0.23
Rotterdam Study 20.54 (1.22) 0.66 20.34 (1.27) 0.79 21.00 (1.26) 0.43 20.40 (1.31) 0.76
SAPHIR Study 21.73 (1.49) 0.25 22.10 (1.50) 0.16 22.03 (1.59) 0.20 22.27 (1.59) 0.15
Utah Cases 21.16 (1.57) 0.46 21.42 (1.58) 0.37 20.29 (1.77) 0.87 20.40 (1.78) 0.82
Utah Controls 23.37 (1.72) 0.05 23.31 (1.72) 0.05 21.95 (1.90) 0.30 21.88 (1.90) 0.32
Pooled analysisa 21.18 0.007 21.48 7.993 1024, b 20.99 0.04 21.19 0.01b
HDL Cholesterol, mg/dl
Bruneck Study 20.89 (0.89) 0.32 20.65 (0.89) 0.47 20.98 (0.95) 0.30 20.94 (0.95) 0.32
KORA S3/F3 Study 21.55 (0.65) 0.02 21.14 (0.65) 0.08 21.39 (0.72) 0.05 20.91 (0.72) 0.20
KORA S4/F4 Study 20.21 (0.53) 0.69 20.05 (0.53) 0.93 20.96 (0.59) 0.11 20.78 (0.59) 0.19
CoLaus Study 20.33 (0.35) 0.30 20.15 (0.35) 0.66 20.40 (0.39) 0.35 20.19 (0.39) 0.62
SHIP 0.44 (0.43) 0.91 0.15 (0.43) 0.73 0.21 (0.45) 0.64 0.28 (0.45) 0.53
Rotterdam Study 0.29 (0.31) 0.35 20.02 (0.37) 0.96 20.49 (0.32) 0.13 20.34 (0.38) 0.37
SAPHIR Study 20.06 (0.58) 0.92 0.38 (0.57) 0.51 20.70 (0.62) 0.26 20.40 (0.61) 0.52
Utah Cases 20.27 (0.56) 0.63 20.20 (0.57) 0.72 20.16 (0.64) 0.81 20.13 (0.64) 0.84
Utah Controls 20.89 (0.80) 0.26 20.83 (0.79) 0.29 20.94 (0.89) 0.29 20.86 (0.88) 0.33
Pooled analysisa 20.14 0.40 20.14 0.40 20.49 0.005 20.32 0.08
Triglycerides, mg/dlc
Bruneck Study 0.039 (0.028) 0.16 0.029 (0.027) 0.28 0.026 (0.030) 0.38 0.024 (0.029) 0.41
KORA S3/F3 Study 0.028 (0.034) 0.40 0.004 (0.034) 0.91 0.027 (0.039) 0.48 0.005 (0.039) 0.90
KORA S4/F4 Study 0.002 (0.021) 0.92 20.014 (0.020) 0.50 0.001 (0.023) 0.98 20.015 (0.023) 0.52
CoLaus Study 20.002 (0.01) 0.86 20.01(0.01) 0.20 20.0007 (0.01) 0.95 20.01 (0.01) 0.28
SHIP n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Rotterdam Study 0.001 (0.015) 0.95 0.009 (0.016) 0.06 20.018 (0.016) 0.26 20.023 (0.017) 0.17
SAPHIR Study 20.012 (0.022) 0.59 20.036 (0.021) 0.09 20.013 (0.023) 0.57 20.030 (0.023) 0.19
Utah Cases 20.074 (0.027) 0.007 20.073 (0.028) 0.008 20.067 (0.031) 0.03 20.065 (0.031) 0.04
Utah Controls 20.017 (0.032) 0.59 20.019 (0.031) 0.54 20.017 (0.035) 0.62 20.019 (0.035) 0.59
Pooled analysisa 20.003 0.60 20.011 0.10 20.006 0.35 20.016 0.03
Values are provided as effect size and standard error.
ALT, alanine-aminotransferase; n.d., not determined.
aPooled effect sizes and P-values derived from meta-regression using a fixed effects model.
bStill significant after correction for multiple testing, using Bonferroni–Holm procedure assuming 10 independent tests.
cValues for triglycerides are calculated based on log-transformed regression and provided only for fasting participants not taking fibrates which were 675 in KORA
S3/F3, 1789 in KORA S4/F4, 5389 in CoLaus, 2038 in Rotterdam. Participants of SHIP were non-fasting at the time of blood collection.
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cholesterol metabolism. We found a definite combination of
binding sites for SREBP factors and the CCAAT binding
factor NFY, a known interactor of SREBP factors (13). This
combination of binding sites (14) could also be detected in
the promoter regions of LPL and LIPC (for details, see Sup-
plementary Material, Fig. S3) and was previously reported to
mediate the sterol response in the promoter of the glycerol-3-
phosphate acyltransferase during the differentiation of preadi-
pocytes to adipocytes (15). More generally, SREBP factors are
known to play a prominent role in the regulation of cholesterol
metabolism (16–18).
Finally, expression profiles were retrieved in BioGPS (https://
biogps.gnf.org/) and showed a strong expression of
adiponutrin in the liver and the adrenal cortex (see Supplemen-
tary Material, Fig. S4). Since adrenocortical hormones are syn-
thesized from cholesterol, this finding may further underline a
possible yet unknown role of adiponutrin in cholesterol
metabolism.
DISCUSSION
Our study revealed a significant association of genetic variants
within the adiponutrin gene with total cholesterol, non-HDLC
and LDLC levels which remained significant after correction
for multiple testing. The findings were consistent in six of
the eight study populations for the rs738409 SNP and the
six studies represented 72% of the investigated individuals.
For the intronic rs2072907, SNP results were consistent
across all eight study populations. The populations varied con-
siderably in study design and recruitment procedures which
points to a stable and biologically important interconnection.
Two recent genome-wide association studies identified
the adiponutrin gene to be associated with liver-related
phenotypes (7,10). Yuan et al. (10) observed a strong associ-
ation of genetic variants within adiponutrin with alanine-
aminotransferase concentrations in European and Asian
Indian populations. Romeo et al. (7) found rs738409, the
common SNP investigated also in our populations, to be sig-
nificantly associated with increased hepatic fat content in a
population of Hispanic, African-American and European-
American individuals and with liver enzymes in Hispanics.
Despite the observed association with hepatic fat content
and the strong involvement of the liver in lipid metabolism,
they surprisingly did not find an association with parameters
of lipid metabolism in their primary analysis sample.
However, in a corresponding analysis in the ARIC study, the
authors obviously observed an additive effect for total choles-
terol in about 11 000 European-Americans (overall P-value ¼
0.014) for the rs738409 (7), which is in support of our find-
ings. One might ask whether the observed association
between adiponutrin variants and lipoprotein levels are
simply a consequence of an impaired liver function as recent
studies observed these variants to be associated with liver
enzyme levels (7,10). This can clearly be excluded for our
investigation, since an adjustment of lipoprotein parameters
for enzymes such as alanine-aminotransferase did not attenu-
ate but strengthened the association. This suggests that liver
enzymes are not in the main causal pathway for the association
between these variants and lipoprotein metabolism in a sense
that an impaired liver function originating from genetic vari-
ation of adiponutrin mocks the association with cholesterol
levels (19).
Several important observations were made in our and other
studies which point to a function of adiponutrin in lipid metab-
olism. The mechanisms underlying this genetic association,
however, remain to be elucidated. The accumulation of fat
in the liver may be due to impaired release of triglyceride-
rich lipoproteins by the hepatocyte into the blood stream.
Our study provides evidence that adiponutrin is involved in
the metabolism of apoB-containing lipoproteins, possibly by
participating in the post-prandial packaging of these lipopro-
teins in the liver. In contrast, this variant was not associated
with HDLC levels. The involvement in the metabolism of
apoB-containing lipoproteins is supported by our bioinfor-
matic analysis. Adiponutrin is possibly co-regulated with
fatty acid synthase and controlled by sterol regulatory
element-binding proteins (SREBPs). SREBPs play a promi-
nent role in the regulation of cholesterol and fatty acid metab-
olism (16–18). In the nucleus, SREBP-1c transcriptionally
activates most genes required for fatty acid synthesis and lipo-
genesis, whereas SREBP-2 preferentially activates cholesterol
synthesis (16–18,20). Indeed, the adiponutrin gene exhibits
features of lipogenic genes. In addition to SREBPs, PPAR g
and the carbohydrate responsive element binding protein
(ChREBP), a new transcription factor mediating glucose
action in liver, were reported to regulate adiponutrin (1,21).
From the data available about adiponutrin in other studies
(5,7,22), it was hypothesized that adiponutrin might mostly
be involved in triglyceride metabolism. We indeed observed
a slight association between our investigated variants and
plasma triglyceride levels which was most pronounced in the
Utah cases of severe obesity (P ¼ 0.008). From this data, we
carefully speculate that per copy of the minor allele G the
functional activity of the enzyme is higher which shifts
more triglycerides into the hepatic cells especially in severely
obese persons who are usually exposed to a higher nutritional
intake. This is in line with the higher hepatic triglyceride
content in carriers of the minor allele of rs734809 observed
by Romeo et al. (7). Whether the triglyceride association
holds true in severely obese individuals as indicated in the
Utah Obesity Case-Control Study needs confirmation in
other large studies.
The investigated variants decreased apoB-containing lipo-
protein fractions by 3% and the association was observed
per copy of the minor allele (7). The variants explained less
than 1% of the lipoprotein concentrations on a population
level. It will therefore require a large number of patients and
controls to find an association of these variants with endpoints
such as cardiovascular disease, diabetes mellitus or the meta-
bolic syndrome. Because the adiponutrin variant is associated
with lower levels of atherogenic lipoproteins, one may
wonder whether this enzyme may represent an attractive drug
target for prevention of cardiovascular disease. However, one
may keep in mind that pharmacological modulation of this
enzyme, if feasible, may be associated with liver steatosis as
it was reported for microsomal transport protein inhibitors (23).
In summary, our results clearly support the association of
adiponutrin with apoB-containing lipoprotein fractions in
West-Eurasian populations not only in studies recruited from
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general or healthy working populations but also from severely
obese populations. Our and previous studies suggest that adi-
ponutrin might mainly be involved in processes related to dis-
turbed lipid and energy metabolism and fat accumulation
especially in the liver.
MATERIALS AND METHODS
Study populations
The investigated populations are of West-Eurasian origin and
are described in detail in the Supplementary Material. Briefly,
the Bruneck Study (n ¼ 800) is a prospective population-based
gender- and age-stratified random sample of all inhabitants of
Bruneck, Italy, designed to investigate the epidemiology and
pathogenesis of atherosclerosis (24,25). The KORA cohorts
(Cooperative Health Research in the Region of Augsburg, KOo-
perative Gesundheitsforschung in der Region Augsburg) are
several cohorts representative of the general population in
Augsburg, Germany, and two surrounding counties that were
initiated as part of the WHO MONICA Study. For the present
analyses, we chose 1644 subjects from the KORA S3/F3
survey, which were part of the recent genome-wide association
study (26,27), as well as 1814 subjects from the KORA S4/F4
survey. The Caucasian Cohorte Lausannoise (CoLaus Study,
n ¼ 5435) is a non-stratified random sample of the population
registry of the city of Lausanne, Switzerland and investigates
the epidemiology and genetic determinants of cardiovascular
risk factors and the metabolic syndrome (28). The Study of
Health in Pomerania (SHIP) (n ¼ 4012) is a population
sample aged 20–79 years selected using population registries
(29). The Rotterdam Study is a prospective cohort study that
started in 1990 in Ommoord, a suburb of Rotterdam, among
10 994 men and women aged 55 and over (30). The Salzburg
Atherosclerosis Prevention Program in Subjects at High Indi-
vidual Risk (SAPHIR) is an observational study conducted in
a healthy working population (n ¼ 1738) recruited by health
screening programs in large companies in and around the city
of Salzburg, Austria (31). The Utah Obesity Case-Control
Study (n ¼ 1864) is composed of 1037 subjects recruited for
severe obesity (BMI between 33 and 92 kg/m2) and a general
population sample of 827 persons of the same ethnicity (32–
34). Informed consent was obtained from each participant.
For the analyses of total, LDL and non-HDL cholesterol, we
excluded all study participants receiving statins as
lipid-lowering drugs. Individuals receiving fibrates were
excluded for the analysis of triglyceride levels.
Genotyping and phenotyping
Genotyping of the non-synonymous SNP rs734809 (a C/G
transversion polymorphism) within exon 3 and of the C/G trans-
version polymorphism rs2072907, a non-coding variant located
in intron 5, within the gene encoding for adiponutrin was done
using a 50 nuclease allelic discrimination (Taqman) assay in all
subjects with sufficient amount and quality of DNA (for details,
see Supplementary Material). For KORA S3/F3 and S4/F4, the
CoLaus Study and SHIP genotypes were derived from an
imputed SNP data set derived from genotyping with Affymetrix
chips with a high imputation quality. In the Rotterdam Study,
rs734809 was genotyped within an Illumina HumanHap 550 k
chip and rs2072907 was imputed. Methods on the measurement
of total cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol, triglycerides and alanine-ami-
notransferase are provided in the Supplementary Material.
Non-HDLC levels were calculated by subtracting HDLC from
total cholesterol. Participants of the Bruneck, KORA S4/F4,
CoLaus, SAPHIR and Utah Study were fasting at the time of
blood collection with the exception of a few individuals. In
KORA S3/F3, 675 of the 1644 subjects were fasting. In the
SHIP Study, blood collection was performed in non-fasting
state. In the Rotterdam Study, TC and HDLC levels used in
this analysis were measured in non-fasting people (baseline
study), while TG was measured in fasting people (third
follow-up examination). Non-fasting individuals of each
study were excluded from the analysis of triglyceride levels.
Statistical analysis
Differences of lipid parameters between the genotype groups
of each study population were tested using general linear
regression models adjusted for age, gender and alanine-
aminotransferase using an unconstrained genetic model as
well as an additive genetic model. A pooled effect size was
obtained by meta-regression analysis using a fixed effects
model and compared to a random effects model (35–37).
Further details are described in the Supplementary Material.
Bioinformatic analysis
We examined the protein domains of adiponutrin that could
potentially influence the cholesterol metabolism by using the
BioSapiens DASTY tool (http://www.biosapiens.info/page
.php?page=dasty) and we investigated the effects of the
amino acid exchange caused by a transversion at rs738409
on the protein function using Polyphen (38) and SIFT (39).
Known and predicted protein interactions were analyzed by
STRING 8.0 (http://string.embl.de/) (11). The potential regu-
lation of the adiponutrin gene promoter by cholesterol-related
transcription factors was investigated using the Genomatix
Suite (Genomatix GmbH, Munich, Germany; www.
genomatix.de). Expression profiles were retrieved by
BioGPS (https://biogps.gnf.org/).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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